Pharmacogenetic Study in Patients With Relapsing Forms of Multiple Sclerosis Who Developed ITP After Receiving Lemtrada

• Status: Not yet recruiting
• Trial end date: 2019-06-01
• Target enrollment: 35
• Participant gender: All

Summary

Primary Objective:

To assess in a new cohort of patients pre-identified candidate single nucleotide polymorphism (SNPs) associated to the development of immune thrombocytopenic purpura (ITP) after LEMTRADA treatment in relapsing multiple sclerosis (RMS) patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genzyme, a Sanofi Company
• Treatments: Alemtuzumab

Criteria

Inclusion criteria :

• Male and female adult patients who have been treated with LEMTRADA, as per label, with development of immune thrombocytopenic purpura (ITP) subsequent to treatment. Patients do not need to be currently on LEMTRADA treatment.

• Patients who have signed the study informed consent form (ICF).

Exclusion criteria:

• Not applicable

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.